TCT-523 Percutaneous Coronary Intervention For Chronic Total Coronary Artery Occlusion With The Implantation Of Bioresorbable Everolimus-Eluting Scaffolds: Poznan CTO-Absorb Pilot Registry  by Lesiak, Maciej et al.
J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y , V O L . 6 6 , N O . 1 5 , S U P P L B , 2 0 1 5 B213TCT-521
Clinical outcomes after bioresorbable scaffold implantation in patients
with a high prevalence of complex lesions: the Milan experience
Hiroyoshi Kawamoto,1 Azeem Latib,1 Neil Ruparelia,1 Akihito Tanaka,1
Alessandro Sticchi,2 Francesco Giannini,2 Alaide Chieffo,2
Mauro Carlino,2 Matteo Montorfano,2 Antonio Colombo1
1EMO GVM Centro Cuore Columbus/San Raffaele Scientiﬁc Institute,
Milan, Italy; 2San Raffaele Scientiﬁc Institute, Milan, Italy
BACKGROUND Bioresorbable scaffolds (BRS) have the potential to
revolutionize the treatment of coronary artery disease. To date,
limited trial data have demonstrated favorable short- and longer-term
clinical outcomes up to a maximum of 5 years. However, these ob-
servations have been limited to patients presenting with ‘simple’
coronary lesions. Outcomes following BRS use in complex lesions
have been described by a few registries but remain poorly character-
ized. We report the clinical outcomes of our “real-world” experience
following BRS implantation in a patient cohort that includes a high
prevalence of complex lesions.
METHODS A retrospective analysis of consecutive patients who un-
derwent percutaneous coronary intervention (PCI) with BRS
(ABSORB; Abbott Vascular, Santa Clara, CA) in 2 centers in Milan be-
tween May 2012 and April 2015.
RESULTS The mean age was 63.810.7 years. The prevalence of dia-
betes mellitus was 25.8%, chronic kidney disease (estimated glomer-
ular ﬁltration rate < 60 ml/min/1.732) was 19.8%, and 13.7% of patients
presented with an acute coronary syndrome. With regards to lesion
characteristics, BRS were implanted in ACC/AHA Type B2/C lesions
(74.3%), CTO (6.0%), bifurcations (46.9%), in-stent restenosis (4.9%),
and left main coronary artery (2.6%). The main target vessel was the
left anterior descending artery (61.7%). The mean SYNTAX score was
17.3  10.4. Meticulous lesion preparation and aggressive post-dila-
tion was recommended for all cases with pre- and post-dilation per-
formed in 98.0% and 99.7%, respectively. A scoring balloon was
utilized in 14.6%. Intravascular ultrasound (IVUS) was utilized in
83.7% of patients to guide therapy. The median follow-up period was
441 days (interquartile range 150 to 503 days). The incidence of major
adverse cardiac events (MACE; deﬁned as a combination of all-cause
death, follow-up myocardial infarction and target vessel revasculari-
zation) occurred in 10.1% at 1-year follow-up (calculated with Kaplan–
Meier analysis). All-cause death occurred in 2 patients (non-cardiac
death). The incidence of target lesion revascularization (per lesion)
and vessel revascularization were 6.3% and 8.9%, respectively. Deﬁ-
nite scaffold thrombosis occurred in 2 patients (1.2%), the ﬁrst
following BRS implantation for the treatment of ST-elevation MI and
the second was late scaffold thrombosis in a patient that prematurely
stopped clopidogrel 2 months after BRS implantation.
CONCLUSIONS Our “real-world” BRS experience that included a high
prevalence of complex lesions demonstrated excellent clinical out-
comes at 1-year. Notably, the incidence of scaffold thrombosis was low
(1.0% at 1-year). Meticulous lesion preparation with non-compliant or
scoring balloons and IVUS-guided BRS implantation are likely to be
important factors in optimizing outcomes and reducing clinical
events.
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BACKGROUND The number and distribution of stent struts has been
previously reported to affect neointimal coverage of metallic drug-
eluting stents (DES), and stented areas with fewer struts and larger
inter-strut angles have been associated with excess neointimal hy-
perplasia compared to areas with more crowded struts. Everolimus-
eluting bioresorbable scaffolds (BRS) are novel coronary implants
that provide short-term vascular scaffolding combined with drug-
delivery capability. However, the thicker struts of current generation
BRS create areas of low endothelial shear stress, which maycontribute to neointimal formation. The aim of the present study is
to investigate the relationship between the number and distribution
of BRS struts and neointimal coverage using optical coherence to-
mography (OCT).
METHODS This study includes 35 patients (42 lesions) treated with
BRS and followed-up with coronary angiography and OCT at 12 (11.8 
2.6) months after the index procedure. All patients were prescribed
lifelong aspirin (100 mg/d) and prasugrel (10 mg/d) for at least 6
months according to local institutional guidelines. Cross sectional
areas (CSA) of OCT images were analyzed at 1-mm intervals. Scaffold
area and neointimal thickness were evaluated. Additionally, scaffold
eccentricity (SE) was deﬁned as follows: SE ¼ (maximum diameter –
minimum diameter)/ maximum diameter. To assess the impact of
strut distribution, CSAs of BRS were divided into four regions. The
average neointimal thickness (ANT) and the number of struts in each
region were measured. The number of struts in each region was
classiﬁed into 1, 2, 3 and  4. The ANT acquired in each area was
divided by the ANT of all struts in the same CSA to describe an ANT
unevenness score, and its maximum and minimum values were
deﬁned as maximum and minimum unevenness score.
RESULTS The mean age of the study population was 5810 years and
23 (65%) were males. Mean scaffold diameter and length were
3.170.37 and 19.95.2 mm, respectively. Pre-dilatation was per-
formed in almost all lesions (90%) and post-dilatation rate was 72%.
There was a signiﬁcant difference in the unevenness score between
regions with different strut numbers (unevenness score ¼ 1.040.34
in regions with 1 strut (n¼401); 0.970.25 in regions with 2 struts
(n¼512); 1.000.25 in regions with 3 struts (n¼664); and 1.040.20 in
regions with 4 struts (n¼691); p¼0.01). A positive signiﬁcant corre-
lation was observed between SE in each CSA and the dispersion
(heterogeneity) of neointimal proliferation in the same CSA, which
was expressed as maximum unevenness score – minimum uneven-
ness score (n¼631, R¼0.10, p¼0.02).
CONCLUSIONS Unlike metallic DES, not only spare distribution of
struts but also crowding of struts is associated with increased neo-
intimal proliferation after BRS implantation. In addition, SE is asso-
ciated with uneven neointimal proliferation. Adequate lesion
preparation prior to BRS implantation is therefore recommended so
that BRS can expand as evenly as possible.
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BACKGROUND The data concerning the use of bioresorbable vascular
scaffolds (BVS) for coronary chronic total occlusion lesions (CTO) are
limited. The aim of the study was to evaluate the early and long-term
clinical outcomes of CTO stenting with BVS.
METHODS The study is a prospective, nonrandomized clinical pilot
registry of patients with CTO lesion located in a major coronary ar-
tery, treated with everolimus-eluting scaffolds. Patients were eligible
if they had symptoms and/or documented reversible myocardial
ischemia, with the presence of viable myocardium in territory sup-
plied by the occluded vessel, assessed by cardiac magnetic resonance
imaging (CMRI). Patients with reference vessel diameter above
4 mm, metallic stents in the target vessel, excessive calcium and
tortuosity were excluded. Subjects were enrolled after successful
recanalization of the target vessel, conﬁrmed intraluminal distal wire
position with no major intraprocedural complications. All patients
were instructed to remain on DAPT for 12 months post procedure,
and then lifelong on aspirin alone. Clopidogrel was used until March
2014, when it was replaced with ticagrelor for at least three months
post procedure.
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diabetics 30%) with CTO treated with BVS were enrolled. A total of 63
BVS were implanted with the average number of 1.6 per patient, and
the scaffold length of 42.4  21.5 mm. Mean J-CTO score was 1.6.
Antegrade approach was used in 38 patients (95%), and retrograde,
after failed antegrade, in the remaining two (5%). High pressure post-
dilatation was performed in 38 patients. Procedural success was
achieved in all patients with no device-related complications. IVUS
was used in two, whereas OCT in ten patients. On QCA the mean in-
scaffold ﬁnal MLD was 2.13  0.31 mm and residual stenosis 13.90 
7.59%. In OCT analysis, performed in 10 patients, the minimal in-
scaffold luminal diameter was 2.65  0.45 mm, minimal luminal area
6.15  0.20 mm2, and lumen area stenosis 17.7  11.1%. At follow-up
(median time 434 days), there were no deaths, one patient experi-
enced subacute and late scaffold thrombosis (ST), another one
developed symptomatic in-scaffold focal restenosis treated with
repeat PCI. At control angiography, performed at the median time of
264 days in 23 patients (58%), the mean in-scaffold diameter stenosis
was 22.42  12.74, and the mean late lumen loss was 0.24  0.55 mm.
No more restenosis or vessel reocclusion was found.
CONCLUSIONS Stenting of coronary CTO lesions with bioresorbable
everolimus-eluting scaffolds is feasible with excellent acute perfor-
mance and good early and long-term clinical outcomes. Adequate
stenting technique and optimal DAPT is of crucial importance. The
results of our study represent a major step forward towards more
complete implementation of BVS to coronary interventions.
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BACKGROUND The bioresorbable vascular scaffold (BVS) is a new
therapy that provides transient vessel support with drug delivery
capability, potentially without the limitations of permanent metallic
implants. It can be an alternative option to currently used drug eluting
stents (DES) for percutaneous coronary intervention (PCI) of ischemic
coronary artery disease (CAD). We aimed to compare the non-inferi-
ority of BVS use to DES.
METHODS We searched Pub Med and Cochrane through June 2015 for
all randomized clinical trials (RCTs) that directly compared BVS and
DES for ischemic CAD. Primary outcome was target vessel revascu-
larization (TVR). Secondary outcomes included cardiac death, acute
myocardial infarction, and deﬁnite or probable stent thrombosis (ST).
We used Fixed or Random Effect analysis using the Cochrane Hand-
book of Systematic Reviews and RevMan 5.2 for statistical analysis.
RESULTS Out of 257 articles, four randomized trial studies were
included. The pooled data provided 3873 patients; 2024 treated with
BVS and 1849 with Everolimus drug-eluting stent. Mean follow up was
12 months. There was a trend towards lower TVR in BVS group
compared to Everolimus group (2.7% vs. 4.5%, p¼0.1) (Figure 1). There
was no difference in cardiac death (0.7 % vs. 0.7%, p¼0.8), AMI (3.4%
vs. 3.4%, p¼0.9) and ST (0.6% vs. 0.7%, p¼0.9) between the two
groups (Figure 2).CONCLUSIONS Our analysis showed similar outcomes between two
treatment modalities. This suggests that BVS might not be inferior to
DES for PCI of ischemic CAD. Further randomized trials should be
pursued to conﬁrm those ﬁndings.
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BACKGROUND Bioresorbable scaffolds (BRS) are an attractive option
for the percutaneous treatment of coronary artery disease due to the
potential advantages associated with its complete absorption within
3-4 years of implantation. However, due the current design of BRS
with thicker struts compared to contemporary metallic stents, some
concern remains that this property may be associated with adverse
events including thrombosis and restenosis when using small BRS.
METHODS Among 350 consecutive lesions treated with Absorb BRS
during May 2012 – Apr 2015 at 2 high volume centers in Milan, 116
lesions were treated using 2.5 mm BRS (small BRS group) and 234
lesions were treated with BRS >2.5 mm BRS (large BRS group). Out-
comes including target lesion revascularization (TLR) per lesion and
deﬁnite stent thrombosis were investigated.
RESULTS The number of BRS was higher and the total BRS length was
longer in the small BRS group when compared to the large BRS group
(1.7  0.8 vs 1.4  0.6; p<0.001, and 42.3  22.6 mm vs 30.7  15.0mm;
p<0.001, respectively). As expected, the post procedural minimum
lumen diameter was signiﬁcantly smaller in the small BRS group (2.36
 0.43mm vs 2.82  0.44mm; p<0.001). TLR- free rate (median
